1L, first-line; CGP, comprehensive genomic profiling; ctDNA, circulating tumor DNA; mBC, metastatic breast cancer; MRD, minimal residual disease; OS, overall survival; PD-L1, programmed death-ligand 1; SOC, standard of care.

*Non-unique lives covered across Guardant360 Liquid CDx and Guardant360 Tissue, including overlap across tests and payers.

References: 1. Parikh A, Van Seventer E, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410 2. Janni W, Friedl T, Rack B, et al. Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer. Poster presented at: San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX. Accessed October 8, 2024. doi:10.1158/1538-7445.SABCS23-PS06-06 3. Nakamura Y, Tsukada Y, Matsuhashi N, et al. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. Clin Cancer Res. 2024;30(19):4377-4387. doi:10.1158/1078-0432.CCR-24-1651 4. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 5. Thompson JC, Carpenter EL, Silva BA, et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precis Oncol. 2021;5:510-524. doi:10.1200/PO.20.00321 6. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer. JAMA Oncol. 2019;5(2):173-180. doi:10.1001/jamaoncol.2018.4305 7. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691-4700. doi:10.1158/1078-0432.CCR-19-0624 8. Choi S, Cho SI, Ma M, et al. Artificial intelligence–powered programmed death 
ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response. Eur J Cancer. 2022;170:17-26. doi:10.1016/j.ejca.2022.04.011 9. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 10. Page RD, Drusbosky LM, Dada H, et al. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non–small cell lung cancer. Clin Lung Cancer. 2022;23(1):72-81. doi:10.1016/j.cllc.2021.10.001 11. Aggarwal C, Marmarelis ME, Hwang WT, et al. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non–small-cell lung cancer. JCO Precis Oncol. 2023;7:e2300191. doi:10.1200/PO.23.00191 12. Nakamura Y, Ozaki H, Ueno M, et al. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. Nat Med. 2024. doi:10.1038/s41591-024-03244-8 13. Harvey-Jones E, Raghunandan M, Robbez-Masson L, et al. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. 
Ann Oncol. 2024;35(4):364-380. doi:10.1016/j.annonc.2024.01.003 14. Guardant Health Data on File. May 12, 2026. Guardant Health, Inc. Redwood City, CA.